Professor Ian Gilbert FMedSci FRSE FRSC
Chair of Roscoe Chair in Drug Discovery
Contact
Websites
Research
Medicinal Chemistry
I am a medicinal chemist and my research interests are in the design and synthesis of potential drugs. The mainstay of my work is synthetic medicinal chemistry as part of the Drug Discovery Unit (DDU). Where possible we make extensive use of molecular modeling to guide our synthetic efforts. I have a particular interests in the following aspects of drug discovery:
Neglected diseases such as human African trypanosomiasis, leishmaniasis and malaria.
Chemical validation of drug targets, including novel targets for which there is little or no precedence for drug discovery.
Novel approaches to and paradigms for drug discovery.
Mode of action studies and target identification.
I am Head of Chemistry in the DDU. Our main focuses are on neglected diseases and novel drug targets. The neglected diseases we are tackling are malaria, tuberculosis and the kinetoplastid diseases. We use both target-based approaches and phenotypic approaches (whole parasite screening). We have had particular success in validating the enzyme N-myristoyltransferase as a drug target in human African trypanosomiasis, and in identifying and optimising phenotypic hits. In our novel targets area, we aim to validate novel areas of biology as potential drug targets.
Media availability
I am available for media commentary on my research.
Design and synthesis of potential therapeutic agents
Contact Corporate Communications for media enquiries.
Areas of expertise
- Antimicrobial resistance
- Infectious diseases
- Medicines
Awards
| Award | Year |
|---|---|
| Fellow of the Academy of Medical Sciences | 2021 |
| Fellow of the Royal Society of Edinburgh | 2020 |
Stories
- Type
- Press release
Antimalarial compound discovered at Dundee has potential to simplify malaria medicines
An antimalarial compound invented at the University of Dundee has been shown to be both effective and have a favourable safety profile in an early-stage clinical trial.
- Type
- News
END2AMR launches to accelerate innovation against drug-resistant bacterial infections
END2AMR, a new Innovative Health Initiative (IHI)–funded public-private partnership bringing together academia, SMEs, and industry to accelerate innovation against antimicrobial resistance
- Type
- Press release
£17.9m research grant to discover new treatments for fungal diseases
A team of leading infectious disease scientists from academia and industry have been awarded £17.9 million to identify new drugs to treat fungal infections